Company Filing History:
1 out of 8,373 
1 out of 62 
1 out of 504 
Years Active: 2018
Title: Wu Albert Cheng: Innovator in Cancer Prognostics
Introduction
Wu Albert Cheng is a notable inventor based in Somerville, MA (US). He has made significant contributions to the field of cancer research, particularly in the area of metastatic cancer. His innovative approach focuses on the use of alternatively spliced mRNA isoforms as prognostic indicators.
Latest Patents
Wu Albert Cheng holds a patent titled "Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer." This invention provides a method for identifying a tumor as likely to metastasize. The method involves obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of specific genes related to cell motility, cell adhesion, and actin cytoskeletal remodeling. This innovative approach aims to improve the accuracy of cancer prognosis.
Career Highlights
Throughout his career, Wu Albert Cheng has worked with prestigious institutions, including the Massachusetts Institute of Technology and Montefiore Medical Center. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Wu has collaborated with notable colleagues such as Frank B. Gertler and Christopher Boyce Burge. These collaborations have further enriched his research and innovation in the field of cancer prognostics.
Conclusion
Wu Albert Cheng is a pioneering inventor whose work in cancer research has the potential to significantly impact patient outcomes. His innovative methods for identifying metastatic tumors highlight the importance of advancements in medical science.